This week's innovators to know includes Kenneth Liao of Baylor St. Luke's, Serafina Lalany of Houston Exponential, and Nick Cardwell of McCord. Photos courtesy

Editor's note: In today's Monday roundup of Houston innovators, I'm introducing you to three innovators across industries — from robotics in health care to smart city technology — all making headlines in Houston this week.

Kenneth Liao, chief of cardiothoracic transplantation and mechanical circulatory support at Baylor St. Luke's Medical Center,

Houston cardiac surgeon outpaces much of the country in game-changing robotics

Dr. Kenneth Liao, chief of cardiothoracic transplantation and mechanical circulatory support at Baylor St. Luke's Medical Center, is one of around 50 surgeons in the country considered experts of this new surgery robotics tool. Photo courtesy of Baylor St. Luke's

Dr. Kenneth Liao is the only cardiatric surgeon in Houston — and one of only around 50 in the world — who uses a specific robot to conduct heart surgeries. The robot, known as the da Vinci, was first designed to assist in battlefield procedures.

Now on its fourth generation, the robot allows surgeons like Liao to treat heart diseases and conditions that typically would require open heart surgery through a one-to-two inch incision near the ribs. In many surgeries, it also allows surgeons to keep a patient's heart beating, lowering the risk of stroke.

"It's a totally game changing component to conventional surgery," Liao says. Read more.

Serafina Lalany, chief of staff at Houston Exponential 

Serafina Lalany joins the Houston Innovators Podcast to discuss the Listies. Photo courtesy of Serafina Lalany

Houston tech companies deserve a shoutout, and, after mulling it over for quite a while, Serafina Lalany and her team at Houston Exponential are making it happen with The Listies, a new awards program.

"The idea for The Listies has been in the back of our minds for a long time," says Lalany, chief of staff at HX, on this week's episode of the Houston Innovators Podcast. "There has always been a need in the ecosystem to celebrate the wins and vibrant culture we have here. This is an opportunity to pay homage to that."

The nomination deadline has been extended for the awards. Nominate a worthy startup, person, investor or corporate by Friday, November 6. Click here to submit. And, click here to stream the episode and read more.

Nick Cardwell, vice president of digital innovation at McCord

A new executive hire for McCord is going to focus on bringing smart city technology to Generation Park. Rendering courtesy of McCord

At 4,200 acres, the Generation Park master-planned development is evolving into its own ecosystem of sorts — one that has a huge opportunity for tech and smart city initiatives. Houston-based real estate developer, McCord, has hired Nick Cardwell as vice president of digital innovation. In the newly created role, Cardwell will be tasked with bringing data-driven solutions, digital transformation, and other smart city innovation to Generation Park.

"McCord's vision for Generation Park is the future of commercial development, pushing digital innovation into the forefront and leveraging cutting-edge technologies throughout their portfolio. I am beyond thrilled to join the McCord team and help make that vision a reality," says Cardwell, in the release. "Through the use of experiences, data, and collaborations, we will accelerate learnings and, in turn, advance resources that will truly improve people's lives." Read more.

Dr. Kenneth Liao, chief of cardiothoracic transplantation and mechanical circulatory support at Baylor St. Luke's Medical Center, is one of around 50 surgeons in the country considered experts of this new surgery robotics tool. Photo courtesy of Baylor St. Luke's

Houston cardiac surgeon outpaces much of the country in game-changing robotics

matters of the heart

Dr. Kenneth Liao is pioneering a less invasive form of heart surgery at a time when distanced medicine has become more important than ever with the help of six team members and one robot.

As the chief of cardiothoracic transplantation and mechanical circulatory support at Baylor St. Luke's Medical Center, Liao has performed 116 robotic cardiac surgeries since coming on board in 2019 (as of press time). With Liao at the helm, Baylor St. Luke's has become a top cardiac robotics program in the country and is the only hospital in Houston to practice this highly-specialized form of surgery.

Liao's four-armed robot friend is known as the da Vinci robotic system and was first designed to assist in battlefield procedures. Now on its fourth generation, the robot allows surgeons like Liao to treat heart diseases and conditions that typically would require open heart surgery through a one-to-two inch incision near the ribs. In many surgeries, it also allows surgeons to keep a patient's heart beating, lowering the risk of stroke.

"It's a totally game changing component to conventional surgery," Liao says, who's one of about 50 surgeons in the country with his level of command over the tool.

Once inside, the da Vinci robot uses tiny instruments to perform surgical practices from suturing to cutting to tying a knot all within the rigid chest cage, which in a typical open heart surgery would have to be broken to perform such tasks.

The surgeon, who's seated about 10 feet away from the patient, controls the tools through a joystick connected to a computer console that shows an enhanced 3D view of the patient's chest. Liao says the screen provides a better visual of the heart than if he was seeing it with his own eyes, as it magnifies the field of surgery tenfold. This method also gives surgeons a better view of areas of the heart that they cannot easily see from above during traditional procedures.

The da Vinci can be used for bypass, grafting, pacemaker, and valve repair surgeries, and it has been proven to result in less blood loss and a faster, less painful recovery. Similar technology has also been adopted for prostate and gynecological surgeries. "It gives you the advantage of minimizing the trauma," Liao says.

And though the da Vinci was developed years before the pandemic, it puts patients at a lower risk of exposure to any outside contaminants, Liao adds, as the robot alone is interfacing with the patient through a small port, compared to doctors, nurses, and assistants hovering over an open chest cavity.

"Technology will theoretically reduce a patient's exposure to COVID in the operation room," he says. "I think that's common sense."

Liao was an early adopter of robotics, when the technology was much less user friendly. He performed the first robotic heart surgery in the state of Minnesota in 2003 and has worked with the developers of the da Vinci ever since to help improve the product after many other surgeons dismissed it.

He says today there is a renewed interest in the highly technical process and he believes it will become an emphasis for younger surgeons.

"This generation of surgeons are young and they are very indebted to computer technology and games. For them looking at screens and controlling the hand joystick control is much more familiar than for the older generation that was trained 20 years ago." he says.

The incredible technology helps, too. "A lot of times, as surgeons, we train in the old way. It's very difficult to change the systems," he says. "You need a major technology revolution to change the teaching and training."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.